资讯

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical ...
Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...